Outcome by patient and disease parameters
. | CR rate . | . | Survival . | . | ||
---|---|---|---|---|---|---|
. | % . | P . | % at 4 y . | P . | ||
Type of disease | ||||||
Adverse genetics | 89 | — | 30 | — | ||
Resistant/refractory | 58 | — | 20 | — | ||
Relapse | 59 | .006 | 21 | .05 | ||
Age group y | ||||||
Younger than 40 y | 78 | — | 45 | — | ||
40-49 y | 58 | — | 26 | — | ||
50-59 y | 60 | — | 12 | — | ||
60 y or older | 48 | < .001 | 12 | < .001 | ||
Cytogenetics at initial diagnosis | ||||||
Favorable | 93 | — | 47 | — | ||
Intermediate | 58 | — | 25 | — | ||
Adverse | 56 | .02 | 15 | .04 | ||
Duration of first CR* | ||||||
Less than 6 mo | 15 | — | 4 | — | ||
6-12 mo | 52 | — | 19 | — | ||
1-2 y | 73 | — | 29 | — | ||
2+ y | 77 | < .001 | 27 | < .001 |
. | CR rate . | . | Survival . | . | ||
---|---|---|---|---|---|---|
. | % . | P . | % at 4 y . | P . | ||
Type of disease | ||||||
Adverse genetics | 89 | — | 30 | — | ||
Resistant/refractory | 58 | — | 20 | — | ||
Relapse | 59 | .006 | 21 | .05 | ||
Age group y | ||||||
Younger than 40 y | 78 | — | 45 | — | ||
40-49 y | 58 | — | 26 | — | ||
50-59 y | 60 | — | 12 | — | ||
60 y or older | 48 | < .001 | 12 | < .001 | ||
Cytogenetics at initial diagnosis | ||||||
Favorable | 93 | — | 47 | — | ||
Intermediate | 58 | — | 25 | — | ||
Adverse | 56 | .02 | 15 | .04 | ||
Duration of first CR* | ||||||
Less than 6 mo | 15 | — | 4 | — | ||
6-12 mo | 52 | — | 19 | — | ||
1-2 y | 73 | — | 29 | — | ||
2+ y | 77 | < .001 | 27 | < .001 |
P values are for heterogeneity for type of disease and for trend for age, cytogenetic group, and duration of first CR.
—indicates not applicable.
Relapsed patients only.